ATARA BIOTHERAPEUTICS, INC. Operating Lease Cost
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Operating Lease Cost of $196.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-08-12
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-06-30 was $196.00K, a 69.89% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2026-03-31 was $196.00K, a 94.77% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-12-31 was $350.00K, a 91.36% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for the quarter ending 2025-09-30 was $502.00K, a 88.31% decline year-over-year.
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2025 was $5.25M, a 68.99% decline from fiscal 2024.
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2024 was $16.93M, a 1.52% decline from fiscal 2023.
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2023 was $17.19M, a 20.69% increase from fiscal 2022.
- ATARA BIOTHERAPEUTICS, INC. operating lease, cost for fiscal 2022 was $14.24M, a 272.22% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2026-06-30 | $196.00K 10-Q · filed 2026-08-12 | $391.00K 10-Q · filed 2026-08-12 | $742.00K derived: sum of 3 quarters · filed 2026-08-12 | $1.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $196.00K 10-Q · filed 2026-05-12 | $546.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.05M derived: sum of 3 quarters · filed 2026-05-12 | $1.70M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $350.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $852.00K derived: sum of 2 quarters · filed 2026-03-16 | $1.50M derived: sum of 3 quarters · filed 2026-08-12 | $5.25M 10-K · filed 2026-03-16 |
| 2025-09-30 | $502.00K 10-Q · filed 2025-11-12 | $1.15M derived: sum of 2 quarters · filed 2026-08-12 | $4.90M 10-Q · filed 2025-11-12 | $8.95M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $651.00K 10-Q · filed 2026-08-12 | $4.40M 10-Q · filed 2026-08-12 | $8.45M derived: sum of 3 quarters · filed 2026-08-12 | $12.74M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $3.75M 10-Q · filed 2026-05-12 | $7.80M derived: sum of 2 quarters · filed 2026-05-12 | $12.09M derived: sum of 3 quarters · filed 2026-05-12 | $16.38M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $4.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $8.34M derived: sum of 2 quarters · filed 2026-03-16 | $12.64M derived: sum of 3 quarters · filed 2026-03-16 | $16.93M 10-K · filed 2026-03-16 |
| 2024-09-30 | $4.29M 10-Q · filed 2025-11-12 | $8.59M derived: sum of 2 quarters · filed 2025-11-12 | $12.88M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $4.29M 10-Q · filed 2025-08-11 | $8.59M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $4.29M 10-Q · filed 2025-05-15 | |||
| 2023-12-31 | $17.19M 10-K · filed 2025-03-07 | |||
| 2022-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $8.60M derived: sum of 2 quarters · filed 2024-03-28 | $12.90M derived: sum of 3 quarters · filed 2024-03-28 | $14.24M 10-K · filed 2024-03-28 |
| 2022-09-30 | $4.30M 10-Q · filed 2022-11-08 | $8.60M derived: sum of 2 quarters · filed 2022-11-08 | $9.95M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $4.30M 10-Q · filed 2022-08-08 | $5.65M 10-Q · filed 2022-08-08 | ||
| 2021-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-08 | $2.33M derived: sum of 2 quarters · filed 2023-02-08 | $3.08M derived: sum of 3 quarters · filed 2023-02-08 | $3.83M 10-K · filed 2023-02-08 |
| 2021-09-30 | $998.00K 10-Q · filed 2022-11-08 | $1.75M derived: sum of 2 quarters · filed 2022-11-08 | $2.50M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $749.00K 10-Q · filed 2022-08-08 | $1.50M 10-Q · filed 2022-08-08 | ||
| 2020-12-31 | $3.02M 10-K · filed 2023-02-08 | |||
| 2019-12-31 | $602.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $1.20M derived: sum of 2 quarters · filed 2022-02-28 | $1.85M derived: sum of 3 quarters · filed 2022-02-28 | $2.58M 10-K · filed 2022-02-28 |
| 2019-09-30 | $602.00K 10-Q · filed 2019-11-07 | $1.25M derived: sum of 2 quarters · filed 2019-11-07 | $1.98M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $649.00K 10-Q · filed 2019-08-08 | $1.37M 10-Q · filed 2019-08-08 | ||
| 2019-03-31 | $725.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |